MYASTHENIA GRAVIS TREATMENT MARKET ANALYSIS

Myasthenia Gravis Treatment Market by Medication (Cholinesterase Inhibitors, Corticosteroids, Immunosuppressants, Plasmapheresis, Intravenous immunoglobulin (IVIg), Monoclonal Antibody), by Distribution channels (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

To Be Published : Dec 2024
Code : CMI2625
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Myasthenia Gravis Treatment Market Restraints

Side effects of the drugs used for treating myasthenia gravis are expected to hamper growth of the myasthenia gravis treatment market. For instance, according to BioNews Services, LLC report, in April 2019, high dose combination of cholinesterase inhibitors (ChEIs) and calcineurine inhibitors (CNIs) such as Mestinon and Prograf are responsible for severe muscle cramps in myasthenia gravis patients. Hence, this factor is expected to hinder growth of the myasthenia gravis treatment market.

MYASTHENIA GRAVIS TREATMENT MARKET ANALYSIS

Market Challenges And Opportunities

Myasthenia Gravis Treatment Market Report Snapshots

EXISTING CLIENTELE